VECTUS BIOSYSTEMS LIMITED — Capital/Financing Update 2026

Apr 13, 2026

==> picture [448 x 82] intentionally omitted <==

14 April 2026

Company Announcements Office Australian Securities Exchange

VB4-P5 Renal Compound Transaction

On 17 October 2025 Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) announced that it had signed a binding Term Sheet with XORTX Therapeutics Inc. (XORTX) for the sale of the Company’s VB4-P5 Renal Small Molecule Compound targeting renal fibrosis. Following the finalisation of the various closing provisions, the transaction closed on 14 April 2026 (13 April 2026 in Canada) (Closing) and Vectus has now received a direct shareholding in XORTX, the Canadian biotechnology company listed on both the Nasdaq and TSX Venture Exchange, which is focused on drug development. The consideration for the sale of the Company’s VB4-P5 compound was satisfied by XORTX issuing Vectus with 154,544 common shares (representing 9.9% of XORTX’s issued shares) and 692,150 pre-funded warrants (which can be exercised to receive shares for no additional payment by the Company. This transaction fits with Vectus’ strategy of developing, and carrying out early validation work on, its drug candidates to the point where they become commercially attractive to pharmaceutical partners.

Key Terms

XORTX acquired patents and the intellectual property specifically related to the Company’s VB4-P5 compound, and the data generated by Vectus from its work on the VB4-P5 small molecule and related assets. The Company has received a licence of such patents and intellectual property for potential use in fields other than renal fibrosis and kidney disease. The consideration receivable by Vectus was satisfied at Closing by the issue of securities by XORTX to the Company at a deemed issue price based on a formula in the Term Sheet that, in the aggregate, equalled the purchase price.

The agreement executed between the parties was subject to a number of Closing provisions, including compliance with stock exchange requirements and securities laws under which both Vectus and XORTX operate, and these provisions have now been satisfied.

The Company has entered into a voluntary lockup agreement, for various amounts of the XORTX securities, for periods ranging from 45 days to 180 days after Closing.

Summary

Vectus now has a shareholding position in XORTX and, accordingly, continues to have an interest in the development and commercialisation of VB4-P5, as well as XORTX’s own compounds. Further development and commercialisation of VB4-P5 and other XORTX compounds will require no financial contribution by the Company going forward.

Vectus’ main undertaking continues to be its active program of commercialisation / licensing of the balance of its drug portfolio, including its clinical lead compound, VB0004, managed by C14 Consulting Group, LLC, as previously announced. The Company’s main focus is ongoing discussions on the commercialisation of VB0004, and its emerging leads, VB4-A32 (liver fibrosis) and VB4-A79 (lung fibrosis).

Vectus Biosystems Limited

Ron Shnier Chairman

This announcement was authorised by the Vectus Board of Directors.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Ground Floor, Unit 5, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia Telephone: +61 2 8344 1300, Facsimile: +61 2 9697 0944 Email: info@vectusbiosystems.com.au Website: www.vectusbiosystems.com.au

==> picture [280 x 52] intentionally omitted <==

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) its lead program, XRx-026, for the treatment of gout; 2) its XRx-008 program for ADPKD; and 3) its XRx-101 program for acute kidney and other acute organ injuries associated with respiratory virus infections. In addition, XORTX is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.

About Vectus Biosystems Limited

The Company is developing treatments for fibrosis, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Since listing on the ASX in 2016, Vectus has concentrated on the development of the Company’s lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 has progressed through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies, its Human Phase Ia and Ib human trials of VB0004, and the advancement of other drugs in its library. This fits with the Company’s strategy of developing, and carrying out early validation work on, its library of drug candidates to the point where they become commercially attractive to pharmaceutical partners.